In the lead up to ASCO 2019, the results of several late stage clinical trials on metastatic hormone sensitive prostate cancer (mHSPC) were released. For Canadian clinicians the results are significant and may be practice changing.
What follows is a multi specialist analysis of select Canadian led abstracts as presented at ASCO 2019.
CARE™ Perspectives are based on compiled commentary provided by select Genitourinary (GU) Faculty members.
HSPC and CSPC (castrate sensitive prostate cancer) are used interchangeably and refer to the same prostate cancer disease state that is susceptible to testosterone suppression therapy.